Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 25, 2019. The document serves as a transaction notification regarding insider trading activity rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting a specific securities transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses a sale of ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Transaction Details and Management Commentary
- Insider: Mr. N Hirons, SVP, Global Ethics and Compliance.
- Transaction Type: Sale of Ordinary Shares.
- Volume: 22,178 shares.
- Price: £15.619 per share.
- Date: March 22, 2019.
- Venue: London Stock Exchange (XLON).
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies beyond the statutory disclosure of the transaction.
Investor Verification Checklist
- Verify the total number of shares held by Mr. N Hirons post-transaction to assess remaining exposure.
- Confirm if this transaction aligns with any pre-established trading plans (10b5-1 equivalent) disclosed in other filings.
- Review the company's most recent Form 20-F or quarterly earnings release for actual financial performance metrics, as they are absent here.